In Vivo Induced Antigen Technology (IVIAT) and Change Mediated Antigen Technology (CMAT)

Author(s): Martin Handfield, Jeffrey D. Hillman

Journal Name: Infectious Disorders - Drug Targets
Formerly Current Drug Targets - Infectious Disorders

Volume 6 , Issue 3 , 2006

Become EABM
Become Reviewer
Call for Editor


In this chapter, an overview of in vivo induced antigen technology (IVIAT) and change mediated antigen technology (CMAT) will be presented, including a discussion of the advantages and limitations of these methods. Over fifteen different microbial pathogens have been or are known to be currently studied with these methods. Salient data obtained from the application of IVIAT and/or CMAT to a selection of human and plant pathogens will be summarized. This includes recent reports on Streptococcus pyogenes (Group A) in neurological disorders and invasive diseases, Xylella fastidiosa in Pierces disease, Xanthomonas campestris in bean blight, Salmonella enterica serovar typhi in typhoid fever and Leishmania spp. related infections. Special emphasis will be given to those targets that have been further investigated for the development of novel vaccine, diagnostic and/or antibiotherapy strategies. This encompasses a new point-of-care serological diagnostic test for chronic periodontal diseases. Finally, Mycobacterium tuberculosis in vivo induced products will be described as providing a rational basis for differentiating subjects with primary, dormant or secondary tuberculosis infections, from control subjects who have or did not have prior vaccination with BCG.

Keywords: Virulence, pathogenesis, bacterium, parasite, IVIAT, CMAT, IVET, STM, DFI

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [327 - 334]
Pages: 8
DOI: 10.2174/187152606778249908
Price: $65

Article Metrics

PDF: 6